700 related articles for article (PubMed ID: 30377816)
1. Peripheral CD19
Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
[TBL] [Abstract][Full Text] [Related]
2. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
3. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Wang Y; Chang H; Zhang X; Yin L
Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Ma J; Yu H; Wang H; Zhang X; Feng K
J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
[TBL] [Abstract][Full Text] [Related]
6. Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study.
Bruschi N; Malentacchi M; Malucchi S; Sperli F; Martire S; Sala A; Valentino P; Bertolotto A; Pautasso M; Capobianco MA
Neurol Ther; 2023 Aug; 12(4):1375-1383. PubMed ID: 37166677
[TBL] [Abstract][Full Text] [Related]
7. Effects of Vitamin D and Dexamethasone on Lymphocyte Proportions and Their Associations With Serum Concentrations of 25-Hydroxyvitamin D
Cho EB; Shin JH; Kwon S; Kim J; Seok JM; Kim BJ; Min JH
Front Immunol; 2021; 12():677041. PubMed ID: 34394078
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.
Ongphichetmetha T; Jitprapaikulsan J; Siritho S; Rattanathamsakul N; Detweeratham T; Prayoonwiwat N
Sci Rep; 2024 Feb; 14(1):3503. PubMed ID: 38347079
[TBL] [Abstract][Full Text] [Related]
9. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
[TBL] [Abstract][Full Text] [Related]
10. The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder.
Cho EB; Cho HJ; Seok JM; Min JH; Kang ES; Kim BJ
Neurol Sci; 2018 Mar; 39(3):543-549. PubMed ID: 29349658
[TBL] [Abstract][Full Text] [Related]
11. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
[TBL] [Abstract][Full Text] [Related]
12. Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica.
de Andrés C; Teijeiro R; Saiz A; Fernández P; Sánchez-Ramón S
Neurologia; 2015 Jun; 30(5):276-82. PubMed ID: 24674779
[TBL] [Abstract][Full Text] [Related]
13. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
Cohen M; Romero G; Bas J; Ticchioni M; Rosenthal M; Lacroix R; Brunet C; Rico A; Pelletier J; Audoin B; Lebrun C
J Neurol Sci; 2017 Feb; 373():335-338. PubMed ID: 28131216
[TBL] [Abstract][Full Text] [Related]
14. B cell depleting therapy for multiple sclerosis overlapping with neuromyelitis optica spectrum disorder.
Lu T; Shu Y; Dai Y; Liu X; Chang Y; Huang Q; Kermode AG; Qiu W
Mult Scler Relat Disord; 2018 May; 22():83-85. PubMed ID: 29621743
[TBL] [Abstract][Full Text] [Related]
15. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder.
Nosadini M; Alper G; Riney CJ; Benson LA; Mohammad SS; Ramanathan S; Nolan M; Appleton R; Leventer RJ; Deiva K; Brilot F; Gorman MP; Waldman AT; Banwell B; Dale RC
Neurol Neuroimmunol Neuroinflamm; 2016 Feb; 3(1):e188. PubMed ID: 26819962
[TBL] [Abstract][Full Text] [Related]
16. Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease.
AbdelRazek MA; Casasola M; Mollashahi R; Brodski A; Morin S; Augustynowicz A; Jassim S; Matiello M; Sloane J
Mult Scler Relat Disord; 2022 Mar; 59():103505. PubMed ID: 35121247
[TBL] [Abstract][Full Text] [Related]
17. The Neutrophil-to-Lymphocyte Ratio and the Monocyte-to-Lymphocyte Ratio Predict Expanded Disability Status Scale Score at One Year in Pediatric Neuromyelitis Optica Spectrum Disorder but not in Multiple Sclerosis.
Devlin L; Gombolay G
Pediatr Neurol; 2023 Jun; 143():84-88. PubMed ID: 37044044
[TBL] [Abstract][Full Text] [Related]
18. Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.
Sechi E; Zarbo R; Biancu MA; Chessa P; Idda ML; Orrù V; Lai S; Leoni S; Solla P
J Neuroimmunol; 2021 Sep; 358():577666. PubMed ID: 34298341
[TBL] [Abstract][Full Text] [Related]
19. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder.
Cui L; Jiao J; Zhang Y; Wang R; Peng D; Jiao Y; Zhang W
Mult Scler Relat Disord; 2024 Jun; 86():105600. PubMed ID: 38579568
[TBL] [Abstract][Full Text] [Related]
20. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success.
Greenberg BM; Graves D; Remington G; Hardeman P; Mann M; Karandikar N; Stuve O; Monson N; Frohman E
Mult Scler; 2012 Jul; 18(7):1022-6. PubMed ID: 22261118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
